[Molecular targeted therapy for acute myeloid leukemia].

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous disease, and the accumulation of various chromosomal and genetic abnormalities is considerably involved in its pathogenesis and prognosis. Recently, the disease classification based on molecular abnormalities and novel molecular-targeting therapies has been developed. In Europe and the United States, several agents have been approved for AML and incorporated into...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Combined Modality Therapy
• Share to fms-Like Tyrosine Kinase 3
• Share to Leukemia, Myeloid, Acute